Chip Clark's father was a middle school English teacher near Natick, Massachusetts.
“My dad was a middle school English teacher in one of the local schools.”
Person
Chip Clark is a biotech business executive who spoke with Luke Timmerman on The Long Run about his career, from SmithKline Beecham in Japan and venture capital at Care Capital to Vanda Pharmaceuticals and Genocea's herpes vaccine effort. He says he served as chief business officer of Vanda from 2004 to 2010.
Clark also described his upbringing near Natick, Massachusetts, and his nickname, which his parents chose to tell him apart from his father, also named William. On Genocea, he said several big pharma companies had tried and failed to make a therapeutic genital herpes vaccine. He said a phase three trial of Gen 3 would have cost about $150 million and taken more than three years.
1 episodes · 18 quoted claims
Chip Clark's father was a middle school English teacher near Natick, Massachusetts.
“My dad was a middle school English teacher in one of the local schools.”
Chip Clark's given name is William, the same as his father, and his parents chose the nickname Chip to tell them apart.
“my father is also William and my parents wanted me to have, wanted to call me something other than what they call him which is Bill and for whatever reason they landed on Chip”
Chip Clark says his parents married before the Supreme Court's Loving decision legalized interracial marriage nationwide.
“They got married before interracial marriage was the law of the land. It was pre the loving decision in the Supreme Court.”
After Harvard, Chip Clark joined SmithKline Beecham, now part of GlaxoSmithKline, in a two-year management training program.
“I was fortunate to join what is now Blackstar SmithKline. It was SmithKline Beechin at the time.”
SmithKline Beecham bought Diversified Pharmaceutical Services, a pharmacy benefit manager, and Chip Clark was tasked with implementing it in Japan with limited success.
“And one of the things they did was purchase DPS, Diversified Pharmaceutical Services, a PDM. And my job was to implement that in Japan, which was ultimately not hugely successful”
Chip Clark lived and worked in Japan for four years with SmithKline Beecham.
“though I did live and work there for four years.”
After business school, Chip Clark worked in biotech venture capital at Care Capital in Princeton, New Jersey.
“I ended up in biotech venture capital with some ex-SmithKline Veacham pharma executives at a firm called Care Capital in Princeton”
Chip Clark says The Medicines Company pioneered the model of in-licensing clinical-stage drugs and repurposing them, and Vanda Pharmaceuticals was one of the first fast followers.
“the medicines company really pioneered this model, and I think we were one of the first fast followers on that model.”
Chip Clark served as chief business officer of Vanda Pharmaceuticals from 2004 to 2010.
“I left the firm four years after joining to be the chief business officer at Vanda and had a wonderful experience from 2004 all the way through 2010.”
Chip Clark says several big pharma companies had tried and failed to develop a therapeutic vaccine for genital herpes before Genocea pursued Gen 3.
“several big pharma companies had tried and failed to develop a therapeutic vaccine, an immunotherapy to treat genital herpes”
Genocea's T cell hypothesis held that the herpes virus is mostly invisible to antibodies, so a vaccine should engage T cells instead.
“We call it the T cell hypothesis. The pathogen spends some of its life, or in fact, most of its life, essentially invisible to the antibodies around which vaccines have been designed for decades.”
Chip Clark names Agenus, Vical and an Australian company called Cordon as other developers of genital herpes vaccines.
“A company called Agenus, which has since pivoted itself into focusing almost entirely on immuno-oncology. A company called Vical, a company called Cordon, an Australian company”
Chip Clark says Genocea ran three clinical trials of Gen 3 that mostly showed consistent effects on surrogate endpoints and clinical measures.
“We ultimately ran three clinical trials and, with a few exceptions, showed very consistent impact on both surrogate endpoints as well as clinical measures”
Genocea's phase 2b data for Gen 3 came out in mid-2017, when the company had about a year of cash left.
“our phase 2b data came out in the middle of last year and we at that point had about a year's worth of cash left”
Chip Clark says a phase three trial of Gen 3 would have cost about $150 million and taken more than three years.
“or there was an unwillingness I would say to invest in the phase three program which was going to cost $150 million or so it was going to take three plus years”
Genocea's headcount fell from about 110 to about 70 in its restructuring, and about 20 more employees then left.
“we went from about 110 people to about 70. And then through the attrition, we lost another 20 people.”
Chip Clark says the flu vaccine was effective only about 20 to 30 percent of the time in the season discussed because the wrong strains were predicted.
“And this year, the flu vaccine works, forget the numbers, but it's like 20 % of the time, 20, 30 % of the time, because we guess the wrong strains to try to cover.”
Luke Timmerman notes that NEA, typically a private early-stage investor, took part in Genocea's public-company financing.
“Well, I thought it was interesting that NEA, which is typically a private early stage or early to mid stage investor, they were part of this in a public company.”